Cryopreserved Amniotic Membrane

NASHVILLE, Tenn. — BioTissue’s CAM360 AmnioGraft is showing early success in treating mild to moderate dry eye, according to a company executive here at Optometry’s Meeting.

KIAWAH ISLAND, S.C. — In this Healio Video Perspective from Kiawah Eye, Roger Kennedy, director of marketing for BioTissue, announces the launch of the CAM360 AmnioGraft.

More than half of all patients treated with glaucoma medications have ocular surface disease, which predominantly manifests as dry eye disease.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Marguerite B. McDonald, MD, discusses the use amniotic membranes for dry eye and persistent epithelial defects.

NEW ORLEANS — A single application of cryopreserved amniotic membrane effectively treated signs and symptoms of moderate to severe dry eye disease after just 2 days, according to Damon Dierker, OD, FAAO, at Academy ’23.

Conjunctival melanoma is an uncommon but aggressive ocular malignancy with high potential for metastasis, reported at 25% at 10 years and more than 30% at 15 years.

In this Healio Video Perspective from the ASCRS meeting, Jeff Wongs, MD, discusses a study that investigated the benefits of cryopreserved amniotic membrane to restore the ocular surface to a healthy state.

Historically, pterygium excision techniques were complicated and inconsistent, undermining many surgeons’ confidence and often leading to delays in surgery until the pterygium had progressed into the visual axis.

Corneal collagen cross-linking is a widely adopted therapy for pathologies in which strength of the cornea is compromised.

Bio-Tissue can proceed with a phase 2 study investigating morselized cryopreserved amniotic membrane and cryopreserved umbilical cord following clearance from the FDA, according to a press release.